Retirement Guys Formula LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Retirement Guys Formula LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 5.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,342 shares of the biopharmaceutical company’s stock after purchasing an additional 64 shares during the quarter. Retirement Guys Formula LLC’s holdings in Regeneron Pharmaceuticals were worth $956,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in REGN. CWM LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock worth $2,389,000 after buying an additional 25 shares during the period. Ritholtz Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 17.6% during the third quarter. Ritholtz Wealth Management now owns 729 shares of the biopharmaceutical company’s stock worth $766,000 after buying an additional 109 shares during the period. Creative Planning lifted its stake in shares of Regeneron Pharmaceuticals by 22.7% during the third quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock worth $12,397,000 after buying an additional 2,178 shares during the period. Swedbank AB lifted its position in Regeneron Pharmaceuticals by 10.1% during the third quarter. Swedbank AB now owns 149,363 shares of the biopharmaceutical company’s stock valued at $157,016,000 after purchasing an additional 13,705 shares during the period. Finally, Magnus Financial Group LLC lifted its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. Magnus Financial Group LLC now owns 1,588 shares of the biopharmaceutical company’s stock valued at $1,669,000 after purchasing an additional 20 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 3.6 %

REGN stock opened at $665.46 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock has a market capitalization of $73.13 billion, a P/E ratio of 17.38, a P/E/G ratio of 2.38 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $714.37 and a 200-day simple moving average of $906.38.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.53%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $973.13.

Read Our Latest Report on REGN

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Further Reading

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.